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Evaluations of drugs for the prevention of restenosis after human coronary angioplasty have been disappoint-
ing. Heparin failed to reduce restenosis in a randomized study in Atlanta, Georgia, in patients maintained on
heparin for 24 h. A randomized study in the same centre compared acetylsalicylic acid to anticoagulation with
coumadin. Restenosis was slightly but not significantly less frequent in patients on acetylsalicylic acid. An
American multicentre randomized study comparing a combination of acetylsalicylic acid and dipyridamole to
ticlopidine and to placebo revealed no difference in terms of incidence ofrestenosis. Dipyridamole alone shows
no effect against acute or late coronary artery restenosis. Two calcium antagonists (diltiazem and nifedipine) did
not significantly diminish restenosis in randomized trials. Neither did a thromboxane A2 inhibitor. Only
eicosapentaenoic acid (EPA), an n-3 fatty acid, significantly reduced restenosis in a randomized study using a
high dose. But the same compound proved ineffective in a similar study using a somewhat lower dose.
Despite scientific evidence for the inefficacy of virtually all tested compounds, I do not know of a single
institution that does not continue to discharge its patients after coronary angioplasty on one or several of
them.
Introduction
The mechanism of coronary angioplasty comprises
splitting of the plaque, disrupting of part of the
media, and stretching of the adventitia. The exposure
of smooth muscle cells and collagen to blood fosters
platelet deposition and thrombus apposition. Platelet
and monocyte derived growth factors may stimulate
excessive smooth muscle cell proliferation leading to
restenosis. Restenosis may also be caused by an
organized thrombus. Early platelet adhesion is thus
bound to play an instrumental role in propagating
restenosis. The role of coronary spasm is less appar-
ent but vasomotion may be undesirable during the
healing process of the artery. Finally, late restenosis
(a rare event) may be due to progression of the
atherosclerotic plaque.
The compounds that hypothetically counteract
these mechanisms are summarized in Table 1. Most
of them have been and are being employed experi-
mentally or empirically and some of them have been
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Table 1 Hypothetical regimens to prevent coronary
restenosis
Compounds against
cell proliferation
(e.g., low molecular weight heparin, hirudin, specific
growth factor inhibitor)
thrombosis
(e.g., heparin, warfarin (coumadin), platelet inhibitors)
spasm
(e.g., nitrates, calcium antagonists)
risk factors for atherosclerosis
(e.g., lipid regulators, antihypertensives, antidiabetics)
investigated in controlled prospective trials. Beta-
blockers had been banned from the list of possibly
salutary drugs after coronary angioplasty when one
of the first patients ever to undergo this procedure
died 2 months after angioplasty of the left main stem
and the pathologist found a patent artery which led to
the assumption of a spasm of the left main stem as
cause of death. The beta-blocker the patient was
taking up to his demise was suspected to have pro-
voked the spasm.
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Animal studies
Animal models have little value for testing the
effect of drugs on restenosis because it is impossible
to create arterial stenoses that resemble human coro-
nary artery disease. In rabbits, both acetylsalicylic
acid with dipyridamole and sulfinpyrazone signifi-
cantly decreased the extent of restenosis 4 months
after iliac balloon angioplasty of stenoses created by
previous balloon de-endothelialization and high
cholesterol diet'1' and low molecular weight heparin
and hydrocortisone individually and synergistically
reduced smooth muscle cell proliferation in a similar
model'2'.
Human studies
Studies on pharmacological compounds thought to
prevent restenosis after coronary angioplasty in
humans are numerous but rather unrevealing. They
seem to have had little impact so far on the habits of
prescriptions after successful coronary angioplasty
which include acetylsalicylic acid in practically all,
calcium antagonists in most, and dipyridamole and
nitrates in many centres.
ANTICOAGULANTS
Heparin
Heparin is unanimously accepted as indispensible
during coronary angioplasty. As for the time after
coronary angioplasty, Radwaner in Brooklyn, New
York, found a recurrence rate of 44% in 36 patients
with heparin infusion for an average of 2-5 h com-
pared with 26% in 138 patients with 21 h of heparin
therapy (personal communication). Although this
difference is statistically significant, the study was a
retrospective analysis of patients in whom the hep-
arin therapy had to be stopped before the scheduled
24 h because of local bleeding problems. Thus, the
comparability of the 2 groups is questionable. Yet, a
prospective multicentre study (M-HEART) on 209
patients'3' corroborated this finding showing an
inverse graded relationship between restenosis and
the duration of heparin therapy after successful
angioplasty (Table 2). Both these reports, however,
appear invalidated by a randomized study on 416
patients in Atlanta, Georgia141, that failed to show a
reduction in acute closures or in restenoses in
patients maintained on heparin or dextrose for 24 h.
The respective acute closure rates were 1-8 and
2-4 and the restenosis rates 41% and 37% per
patient with control angiography, which was avail-
able in about 60%. All patients received acetylsalicy-
lic acid in addition.
Table 2 Prolonged heparin infusion and coronary
restenosis^
Duration of heparin infusion Restenosis
(h) (%)
< 2
2-17
17-30
>30
60
48
44
40
Warfarin (coumadin)
Before Andreas Griintzig joined Emory Univer-
sity in Atlanta, Georgia, in late 1980, he used to
anticoagulate his patients with coumadin after coro-
nary angioplasty. Being confronted with the lack of
enthusiasm and practice for a well-conducted anti-
vitamin K anticoagulation in the U.S.A. and in view
of the convincing efficacy of anti-platelet agents in
the prophylaxis of coronary vein graft attrition, a
change of habit in favour of acetylsalicylic acid was
imposed. His critical mind, however, would not let
such a change go by without scrutinizing it with a
randomized trial'5'. After successful angioplasty, 248
patients were randomized to either 325 mg of acetyl-
salicylic acid daily or coumadin with a projected
prothrombin time of 2-2 • 5 times of the normal value.
The restenosis rate in the acetylsalicylic acid group
(126 patients) was 27% as opposed to 36% in the
coumadin group (122 patients). These figures are in
favour of acetylsalicylic acid but the difference was
statistically significant only in the subgroup of
patients with a history of chest pain between 3 and 23
months. Analysing the data in light of patient com-
pliance, it appeared that patients taking hardly any of
the prescribed coumadin pills had a 32% restenosis
rate compared with 20% in patients taking hardly any
of their acetylsalicylic acid pills. Do these figures
provide a hint that very low dose acetylsalicylic acid
might be beneficial?
A more recent study from London, England'6',
compared coumadin plus verapamil with verapamil
alone in a randomized study on 110 patients. The
restenosis rate was 25% per lesion and 29% per
patient for the group with coumadin and 33% and
37%, respectively, for the control group. The differ-
ence was not significant but the statistical power of
the study was rather poor.
A final verdict on coumadin for this indication has
probably to await a randomized single-blind study
conducted in a country with well-instituted infra-
structures for guaranteeing compliance and adequate
prothrombin times.
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Antiplatelet agents
To resume the point alluded to above, that very
low dose acetylsalicylic acid might be a good choice
because it might reduce the synthesis of platelet
thromboxane A2 but not that of vessel wall prosta-
cyclin, we carried out a randomized trial comparing
100 mg of acetylsalicylic acid daily with placebo in a
single-blind fashion'7'. After the inclusion of 40
patients, we stopped the trial because of data
appearing in the literature that, at least for the inter-
vention itself, acetylsalicylic acid is indicated since
acetylsalicylic acid with or without dipyridamole pro-
ved efficacious to diminish the occurrence of fresh
thrombi in dilated lesions and the need for emerg-
ency thrombolysis or bypass surgery in a retro-
spective study from Philadelphia, Pennsylvania'8'. So
far, only one acute vessel occlusion had occurred in
our patients, but it concerned a patient on placebo.
When the follow-up results became available, we
found, to our surprise, that the restenosis rate was
twice as high in the acetylsalicylic acid group (33%)
than in the placebo group (14%).
Our acetylsalicylic acid restenosis rate is in keeping
with the 31% (13/44 patients) of a contemporary study
from Homburg, Germany, using 320 mg daily'9'.
That study randomized the 320 mg dose against
an even higher dose (1500 mg daily) with which it
found a lower restenosis rate (21%, 9/42 patients),
still higher than our result with placebo. Of course all
these cohorts are very small, the confusing results are
far from being statistically significant and, one might
suspect, type 1 errors. Nevertheless, they leave little
hope for acetylsalicylic acid to be effective at any
dose.
This concern is shared by a randomized trial from
Atlanta, Georgia'10', comparing 80 mg of acetylsali-
cylic acid with 1500 mg daily in roughly 500 patients.
Follow-up angiography was available in 166 patients
only, and the restenosis rates were based on these
patients exclusively which, in part, explains their high
values. They were 47% with low and 51% with high
dose acetylsalicylic acid and there were also no differ-
ences between groups regarding acute complication
rates.
Acute complication rates, however, were higher in
a group on placebo in a randomized study comparing
these patients to patients on acetylsalicylic acid
(990 mg daily) and dipyridamole (225 mg daily) in
Montreal, Canada'111. Among the 376 randomized
patients, there were 16 periprocedural myocardial
Q-wave infarctions, 13 in the placebo and three in the
active drug group (P < 0-05). The 127 patients with
follow-up angiography on placebo had a restenosis
rate of 39% compared with 38% of the 122 patients in
the active treatment group. All patients received
heparin for about 12 h after the procedure (500 U
h"1 only) and diltiazem during follow-up.
The conclusion from studies in Munich'12' and
Frankfurt, Germany'13', that dose reduction or dis-
continuation of acetylsalicylic acid is a risk factor for
the development of restenosis has to be challenged.
Acetylsalicylic acid was reduced or stopped mainly
for gastric discomfort in the cases concerned. These
symptoms may have been an expression of a resteno-
sis already present.
As for other platelet aggregation inhibitors, an
American multicentre randomized study compared a
combination of acetylsalicylic acid (650 mg daily)
plus dipyridamole (225 mg daily) with ticlopidine
(750 mg daily) and with placebo and revealed no
significant differences'14'. The restenosis rate in the
65 patients on ticlopidine (29%) appears higher than
the 18% in the 57 patients on acetylsalicylic acid and
dipyridamole, but then again, the restenosis rate in
the 54 patients on placebo was only 20%.
Sulotroban, a thromboxane A2 antagonist, is a
further compound that hypothetically might reduce
restenosis after coronary angioplasty by inhibiting
platelet adhesion and preventing spasm, but it failed
to do so in a small randomized trial in Geneva,
Switzerland, and Munich, Germany'15'. The resteno-
sis rates of 57 patients who compliantly finished a
therapy of 6 months with 3200 mg (eight pills) daily of
sulotroban or undistinguishable placebo pills (42
patients) were 65% and 61%, respectively.
Prostacyclin, finally, administered intravenously
to 116 patients for 48 h after coronary angioplasty at
a dose of 5-7 ng kg"1 min"1 in Calgary, Canada'16' as
an adjunct to acetylsalicylic acid (325 mg daily) and
dipyridamole (225 mg daily) also failed to reduce the
restenosis rate (31%) compared with a randomized
group with placebo infusions in addition to acetylsali-
cylic acid and dipyridamole which yielded a resteno-
sis rate of 32%. Acute complications including death,
infarction, need for emergency bypass surgery, and
ventricular arrhythmia, however, were significantly
less frequent in the prostacyclin group (17% vs 6%,
Calcium antagonists
Calcium antagonists were granted much advance
credit as valuable agents against restenosis based on
early reports that vasospasm leads to restenosis'17'
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and on the hypothesis that vasoactivity may add to
the mechanical endothelial trauma at the basis of
platelet deposition. Two calcium antagonists have
been studied in randomized trials. Both failed to
prevent or significantly diminish restenosis.
Diltiazem (270 mg daily), examined in Montreal,
Canada'18', as a complement to a combination of
acetylsalicylic acid (650 mg daily) and dipyridamole
(225 mg daily), did not significantly reduce the recur-
rence rate in a study on 92 patients followed for 10
months. The recurrence rate was 15% with diltiazem
and 22% without. The mean degrees of stenosis
differed by 1% before, 1% immediately after, and
only 2% (in favour of diltiazem) at follow-up
between the treatment and control group. The mean
loss of diameter during follow-up was 4% in the
diltiazem and 7% in the control group.
Nifedipine (40 mg daily) was examined in Atlanta,
Georgia'19', as an adjunct to acetylsalicyclic acid
(325 mg daily) in a double-blind protocol on 241
patients followed for about 4 months. The restenosis
rate in the 84 patients per group with control angio-
gram and ascertained compliance was not signifi-
cantly different in patients on nifedipine (29%) or on
placebo (33%). Interestingly, there was no differ-
ence either in the frequency or recurrence of chest
pain between treatment and placebo group. Only the
time to recurrence of chest pain was slightly longer in
the nifedipine group.
Steroids
A randomized study with a 5-day regimen of a not
precisely defined high steroid dose in Evansville,
Indiana'20', and with control angiography available in
58 of the 66 patients initially included, found a reste-
nosis rate of 33% for both patients with and patients
without steroids.
This was confirmed for second restenoses in a
similar randomized study in Kansas City, Mis-
souri'21', using 60 mg of prednisone daily for 1
week in addition to nondefined doses of acetylsalicy-
lic acid, dipyridamole, and calcium antagonists in
patients with coronary angioplasty for restenosis.
This study analysed only the 27 compliant patients of
each group with control angiogram (about half of the
patients initially randomized) and found a re-
restenosis in 36% of the lesions in the steriod group
and 40% in the group with the basic therapy only.
Dietary supplements
The single regimen that was able to reduce reste-
nosis in a significant manner in a randomized con-
Table 3 Effect ofeicosapentaenoic acid (EPA) on coronary
restenosis
EPA (18 capsules = 3200 mg
day'^+ASA + dipyridamole
(n = 50)
ASA (325 mg day"1)
+ dipyridamole (225 mg day"1
(n = 53)
EPA (10 capsules = 1800 mg
day"1) + ASA + verapamil
(n = 46)
Placebo + ASA (150 mg day"1)
+ verapamil (240 mg day"1)
(« = 53)
Restenosis
per lesion
16%
36%
28%
32%
Restenosis
per patient
19% A
46%
33% B
34%
A = 6 months follow up1221; B = 4 months follow-up[231; ASA =
acetylsalicylic acid.
trolled trial, albeit in a single one only, did not imply
a drug but a nutrient, i.e., fish oil containing eico-
sapentaenoic acid (EPA), a n-3 fatty acid. A high
content of EPA at the expense of arachidonic acid in
the membrane of platelets decreases the production
of thromboxane A2 and monocyte-derived growth
factors. In Dallas, Texas'22', 82 patients were openly
randomized to acetylsalicylic acid and dipyridamole
with or without 3200 mg (18 capsules!) of EPA
daily. The restenosis rates are summarized in
Table 3.
The value of this finding is put into perspective by a
similar study performed in Melbourne, Australia'23',
which found EPA completely ineffective (Table 3) in
154 randomized patients allocated to 1800 mg
(10 capsules) daily of EPA or placebo in a double-
blind fashion.
Even if the difference in dosage is the reason for
the disparate findings of the two studies, the practical
value of EPA is more than questionable. If a reduc-
tion from 18 to 10 capsules daily of a given compound
annihilates the effect, the therapy has to be discarded
as impracticable.
Conclusions
After 11 years of clinical experience and research
in the field of restenosis after coronary angioplasty,
we have made no palpable progress. We keep on
prescribing drugs to reduce restenosis without any
proof that they are effective. Compounds that have
shown or may show some efficacy, such as EPA, low
molecular weight heparin, and, perhaps, hirudin,
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risk disqualifying themselves by impossible demands
on patient compliance or cost.
Thus the search goes on for, one hopes, a single
drug that reduces platelet aggregation, prevents
spasm, diminishes smooth muscle cell proliferation,
slows atherosclerosis, has no side-effects, and is long
acting (one daily pill). Finally, the prescription of
such a drug over about 6 months to all patients with
successful coronary angioplasty should be cheaper
than repeat angioplasty in every third of them to also
satisfy economists.
I do not need to be a prophet to presage that we will
continue to redilate for quite some time.
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